Back

The SGLT2 inhibitor empagliflozin in patients hospitalised for acute heart failure: a multinational randomised trial

25 August 2023 (14:18 - 14:37)
Organised by: Logo
Congress Presentation Part of: Nature Medicine: highlights in cardiovascular research Chronic Heart Failure ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor Christiane E Angermann

University Hospital of Wurzburg, Wurzburg (Germany)

3 More presentations in this session

Presentation thumbnail
RNA interference targeting hepatic angiopoietin-like protein 3 results in prolonged reductions in serum triglyceride and non-HDL cholesterol concentrations: first human results with ARO-ANG3
Professor G. Watts (Perth, AU)
Slides Video
Presentation thumbnail
Long-term cardiac pathology in individuals with mild initial COVID-19 illness
Doctor V. Puntmann (Frankfurt, DE)
Slides Video
Presentation thumbnail
Machine learning for diagnosis of myocardial infarction using cardiac troponin concentrations
Doctor D. Doudesis (Edinburgh, GB)
Slides Video

Access the full session

Session thumbnail
Nature Medicine: highlights in cardiovascular research
Video

The Event

Event poster

ESC Congress 2023

25 August 2023 14:18 CET
You may be interested in
thumbnail
Congress Presentation
Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction results from the EMPULSE trial.
thumbnail
Congress Presentation
EMPULSE
thumbnail
Congress Presentation
What value do SGLT2 inhibitors offer to patients hospitalised for heart failure?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources